BridgeBio Pharma Long Term Debt 2018-2024 | BBIO

BridgeBio Pharma long term debt for the quarter ending June 30, 2024 was $1.718B, a 0.08% decline year-over-year.

  • BridgeBio Pharma long term debt for 2023 was $1.727B, a 1.12% increase from 2022.
  • BridgeBio Pharma long term debt for 2022 was $1.708B, a 0.22% increase from 2021.
  • BridgeBio Pharma long term debt for 2021 was $1.704B, a 258.05% increase from 2020.

BridgeBio Pharma Long Term Debt 2018-2024 | BBIO

  • BridgeBio Pharma long term debt for 2023 was $1.727B, a 1.12% increase from 2022.
  • BridgeBio Pharma long term debt for 2022 was $1.708B, a 0.22% increase from 2021.
  • BridgeBio Pharma long term debt for 2021 was $1.704B, a 258.05% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$12.6B
Bausch Health Cos (BHC)$3.4B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$2B
Taysha Gene Therapies (TSHA)$307M
Personalis (PSNL)$241M
Assembly Biosciences (ASMB)$106M
Grace Therapeutics (GRCE)$30M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$5M
Teligent (TLGT)$0M